You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國中藥(00570.HK):受讓中藥新藥化濕敗毒顆粒臨牀試驗批件、專利及藥品註冊證書
格隆匯 03-30 18:31

格隆匯3月30日丨中國中藥(00570.HK)公佈,公司透過其控股子公司廣東一方,於2020年3月30日與中國中醫科學院簽署《技術轉讓合同》,以人民幣1.5億元的價格受讓化濕敗毒顆粒(暫定名)臨牀試驗批件、專利及藥品註冊證書。

在此次新型冠狀病毒肺炎疫情中,中醫藥治療應用廣泛,彰顯了中醫藥在應對新發突發重大公共衞生事件中的獨特優勢和作用。化濕敗毒方是由中國中醫科學院醫療科研團隊在武漢抗擊新冠肺炎疫情過程中結合臨牀實踐優化而成,被列入第六版、第七版《新型冠狀病毒肺炎診療方案》。由該方劑製成的化濕敗毒顆粒是我國首個獲批進入臨牀試驗治療新冠肺炎的中藥新藥,具有完全自主知識產權。目前已開展臨牀前動物實驗及臨牀觀察研究,並正在進行前瞻性的隨機對照臨牀試驗,為化濕敗毒顆粒的新藥申報提供了確切臨牀療效證據。在獲得中國中醫科學院轉讓的化濕敗毒顆粒藥物相關研究材料後,廣東一方將利用自身在中藥配方顆粒領域的生產技術領先經驗,加速推進科技成果轉化,在中國中醫科學院的技術指導下組織完成註冊證書申報工作,並在獲得註冊證書後安排化濕敗毒顆粒生產、銷售。

集團將利用長期在製藥領域積累的數據和經驗,結合中國中醫科學院的強大科研實力,優化科研與生產的協同性,進一步提升中藥現代化水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account